RICHARD V. SMALLEY, M.D.; ROBERT L. WALL, M.D., F.A.C.P.
Busulfan (1-4, dimethanesulfonoxybutane) (Myleran®) is at present widely used in the therapy of chronic granulocytic leukemia. It is highly effective when administered either as maintainance therapy or intermittently as required. From 87 to 100% of patients under therapy go into an effective remission of their disease and are able to lead useful productive lives (1-9). Toxicity has remained extremely low; the only serious effect noted has been bone marrow depression, and even this is very unusual if the dosage is kept within prescribed limits. Wilkinson (1) in his review, stated that busulfan appeared to be "singularly free of toxic side
SMALLEY RV, WALL RL. Two Cases of Busulfan Toxicity. Ann Intern Med. ;64:154–164. doi: 10.7326/0003-4819-64-1-154
Download citation file:
Published: Ann Intern Med. 1966;64(1):154-164.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use